P.Happi® Secures $

P.Happi®, a UK-based women’s health startup, has secured $100K in funding.

This investment marks a significant step for the company, which is focused on redefining intimate care through microbiome science. The capital will support P.

Happi®'s ongoing mission to innovate and expand its reach within the women's health sector.

P.Happi® offers a daily serum featuring B.Y.M.® 1405 Bdellovibrio, a breakthrough natural bacterium.

This ingredient is proven to target and break down over 99% of harmful gram-negative bacteria, such as E. coli, while preserving the beneficial lactobacilli crucial for female intimate flora.

Unlike traditional probiotics, Bdellovibrio works topically to help the intimate area stay balanced, moisturised, and protected, especially during common trigger moments like hormonal changes, antibiotic use, sexual activity, and high stress.

Since its launch in 2024, P.Happi® has supported thousands of women across the UK.

The company's approach is trusted by clinicians across multiple specialties, including menopause specialists, vulval dermatologists, pelvic health physiotherapists, urologists, urogynecologists, gynaecologists, sexual health clinicians, and OB-GYNs.

This broad clinical acceptance underscores the scientific foundation of its product.

The newly secured funds are earmarked for strategic growth initiatives. P.

Happi® plans to use the investment to further its product development, enhance its educational outreach, and potentially expand its market presence, ensuring more women can access its innovative care solutions.

The company remains committed to improving the standard of care for women through continued innovation, education, and science that prioritizes everyday wellbeing.